Displaying 1 - 20 of 101 results
Released Company Title Industry Topic
15 Jan 2020
18:00 CET
THERANEXUS THERANEXUS ANNOUNCES THE CLINICAL RESULTS OF ITS PHASE IB STUDY DEMONSTRATING THE EXTENDED PHARMACOLOGICAL PROFILE OF ITS DRUG CANDIDATE THN201 COMPARED TO DONEPEZIL Biotechnology Other subject
15 Jan 2020
18:00 CET
THERANEXUS THERANEXUS ANNONCE LES RÉSULTATS CLINIQUES DE SON ÉTUDE DE PHASE IB MONTRANT UN ÉLARGISSEMENT DU PROFIL PHARMACOLOGIQUE DE SON CANDIDAT MÉDICAMENT THN201 PAR RAPPORT AU DONÉPÉZIL Biotechnology Other subject
12 Dec 2019
18:00 CET
THERANEXUS Theranexus et la fondation BBDF annoncent la conclusion d'un accord de licence exclusive et mondiale pour le candidat-médicament BBDF-101 dans la maladie de Batten Biotechnology Other subject
12 Dec 2019
18:00 CET
THERANEXUS Theranexus and Beyond Batten Disease Foundation (BBDF) announce the signing of a worldwide exclusive license for Batten disease drug candidate BBDF-101 Biotechnology Other subject
15 Oct 2019
18:00 CEST
THERANEXUS THERANEXUS REPORTS CASH POSITION AS OF SEPTEMBER 30, 2019 Biotechnology Sales, Income, Commercial results
15 Oct 2019
18:00 CEST
THERANEXUS THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 30 SEPTEMBRE 2019 Biotechnology Sales, Income, Commercial results
26 Sep 2019
18:00 CEST
THERANEXUS THERANEXUS ANNOUNCES ITS FIRST HALF 2019 RESULTS Biotechnology Sales, Income, Commercial results
26 Sep 2019
18:00 CEST
THERANEXUS THERANEXUS ANNONCE SES RÉSULTATS DU PREMIER SEMESTRE 2019 Biotechnology Sales, Income, Commercial results
24 Sep 2019
18:30 CEST
THERANEXUS NOUVELLE ETAPE FRANCHIE POUR THERANEXUS : INCLUSION DU DERNIER PATIENT DANS L'ETUDE DE PHASE 2 POUR THN102 DANS LA MALADIE DE PARKINSON Biotechnology Other subject
24 Sep 2019
18:30 CEST
THERANEXUS A NEW MILESTONE REACHED FOR THERANEXUS: INCLUSION OF LAST PATIENT IN PHASE II TRIAL FOR THN102 IN PARKINSON'S PATIENTS Biotechnology Other subject
17 Sep 2019
07:30 CEST
THERANEXUS THERANEXUS ANNONCE L'INCLUSION DU DERNIER SUJET DANS SON ÉTUDE DE PHASE 1B POUR THN201 Biotechnology Other subject
17 Sep 2019
07:30 CEST
THERANEXUS THERANEXUS ANNOUNCES INCLUSION OF LAST SUBJECT IN ITS PHASE IB TRIAL OF THN201 Biotechnology Other subject
03 Sep 2019
09:45 CEST
THERANEXUS THERANEXUS ANNOUNCES THE PUBLICATION OF TWO SCIENTIFIC PAPERS AND A PRESENTATION AT THE EUROPEAN PAIN CONGRESS (EFIC) TO BE HELD ON 3-7 SEPTEMBER IN VALENCIA, SPAIN Biotechnology Other subject
03 Sep 2019
07:30 CEST
THERANEXUS THERANEXUS ANNONCE LA PUBLICATION DE DEUX ARTICLES SCIENTIFIQUES ET UNE PRÉSENTATION DE THN101 LORS DU CONGRÈS EUROPÉEN DE LA DOULEUR (EFIC) Biotechnology Other subject
11 Jul 2019
09:30 CEST
THERANEXUS THERANEXUS RAISES APPROXIMATELY 2.2 MILLION EUROS IN A PLACEMENT RESERVED TO A CATEGORY OF PERSONS Biotechnology Other subject
11 Jul 2019
09:05 CEST
THERANEXUS THERANEXUS LEVE 2,2 MILLIONS D'EUROS DANS LE CADRE D'UN PLACEMENT RESERVE A UNE CATEGORIE DE PERSONNES Biotechnology Alliances and agreements, Mergers, Acquiqitions, Transferts
10 Jul 2019
18:50 CEST
THERANEXUS THERANEXUS ANNOUNCES THE LAUNCH OF A CAPITAL INCREASE BY PRIVATE PLACEMENT FOR A MAXIMUM AMOUNT OF EURO 4 MILLION Biotechnology Alliances and agreements, Mergers, Acquiqitions, Transferts
10 Jul 2019
18:45 CEST
THERANEXUS Erratum- THERANEXUS ANNONCE LE LANCEMENT D'UNE AUGMENTATION DE CAPITAL PAR PLACEMENT RÉSERVÉ, D'UN MONTANT MAXIMAL DE 4 MILLIONS D'EUROS Biotechnology Other subject
10 Jul 2019
18:05 CEST
THERANEXUS THERANEXUS ANNONCE LE LANCEMENT D'UNE AUGMENTATION DE CAPITAL PAR PLACEMENT RÉSERVÉ, D'UN MONTANT MAXIMAL DE 4 MILLIONS D'EUROS Biotechnology Alliances and agreements, Mergers, Acquiqitions, Transferts
08 Jul 2019
18:50 CEST
THERANEXUS THERANEXUS REPORTS CASH POSITION AS OF JUNE 30, 2019 Biotechnology Other subject